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Abstract 
Background: The growing need to capture data on health and health events using faster and efficient means to 
enable prompt evidence‑based decision‑making is making the use of mobile phones for health an alternative means 
to capture anti‑malarial drug safety data. This paper examined the feasibility and cost of using mobile phones vis‑à‑vis 
home visit to monitor adverse events (AEs) related to artemisinin‑based combination therapy (ACT) for treatment of 
uncomplicated malaria in peri‑urban Ghana.
Methods: A prospective, observational, cohort study conducted on 4270 patients prescribed ACT in 21 health facili‑
ties. The patients were actively followed by telephone or home visit to document AEs associated with anti‑malarial 
drugs. Call duration and travel distances of each visit were recorded. Pre‑paid call cards and fuel for motorbike travels 
were used to determine cost of conducting both follow‑ups. Ms‑Excel 2010 and STATA 11.2 were used for analysis.
Results: Of the 4270 patients recruited, 4124 (96.6 %) were successfully followed up and analyzed. Of these, 
1126/4124 (27.3 %) were children under 5 years. Most 3790/4124 (91.9 %) follow‑ups were done within 7 days of ACT 
intake. Overall, follow up by phone (2671/4124—64.8 %) was almost two times the number done by home visits 
(1453/4124—35.2 %). Duration of telephone calls ranged from 38 s to 53 min, costing between GH¢0.26 (0.20USD) 
and GH¢41.70 (27.USD). On the average, the calls lasted 3 min 51 s (SD = 3 min, 21 s) costing GH¢2.70 (0.77USD). 
Distance travelled for home visit ranged from 0.65 to 62 km costing GH¢0.29 (0.20USD) and GH¢279.00 (79.70USD). 
Thirty‑two per cent (1128/4124) of patients reported AEs. In total, 1831 AE were reported, 1016/1831(55.5 %) by 
telephone and 815/1831 (44.5 %) by home visits. Events such as nausea, dizziness, diarrhoea, and vomiting were com‑
monly reported.
Conclusion: Majority of patients was successfully followed up by telephone and reported the most AEs. The cost of 
telephone interviewing was almost two times less than the cost of home visit. Telephone follow up should be consid‑
ered for monitoring drug adverse events in low resource settings.
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Background
Information and communication technology has the 
propensity to improve a country’s health delivery system 
leading to positive implications for its health policy strat-
egy [1]. An increasing number of countries in the world 
are using mobile communications to handle and address 
healthcare needs including behaviour change communi-
cation, training, education and awareness creation, data 
collection and monitoring in remote settings, disease 
and outbreak tracking, diagnosis and treatment [2]. The 
use of mobile phones to monitor health outcomes in low 
resourced settings, including Ghana will go a long way 
to reduce cost and maximize data collection within the 
health delivery system.
Malaria management in Africa is drastically hampered 
by poor, incomplete and untimely data on the incidence 
of disease and resource distribution and use, resulting 
in poor planning and implementation of interventions 
to ensure its control and elimination. To effectively deal 
with and sustain malaria control, Africa needs a qual-
ity health management system that can monitor malaria 
drug efficacy and safety. This requires timely and accu-
rate data that is based on an effective and efficient com-
munication network between health service providers 
and their clients [3]. Mobile health (mhealth) is the use 
of portable communication devices for creating, storing, 
retrieving and transmitting data between health service 
providers and their clients to improve the quality of care 
and patient safety [4, 5]. Decreasing cost and increasing 
network coverage has opened up more opportunities for 
many people in developing countries to access and use 
mobile phones and other communication gadgets. With 
the introduction of many and affordable wireless net-
works. Africa has indeed witnessed a significant improve-
ment in communication in many of its rural communities 
and Ghana is no exception [6, 7]. Growing evidence sug-
gests that mobile communication based health has the 
potential of radically improving healthcare in the most 
remote and less endowed communities in the world 
[8]. The use of mobile phone makes it easy for frontline 
health workers to use mobile technology rather than the 
traditional paper-based reporting system to gather and 
present health data with its inherent delays [9].
The growing need to capture data on health and health 
events using faster and efficient means to enable prompt 
evidence-based decision-making is making the use of 
mobile phones for health an alternative to traditional 
paper means of data capture [10, 11]. Growing mobile 
phone usage in Africa therefore offers the opportunity to 
explore its use in non-traditional modes of gathering data 
on health in resource-constrained settings, particularly 
on safety [12]. The use of medicines within the public 
and private health care system to treat large numbers of 
people presents the opportunity to generate real-life data 
on the safety and effectiveness of these medicines. Moni-
toring and documenting the safety of artemisinin-based 
combination therapy (ACT) is critical for public health 
programmes as any harm to a few patients, even if unre-
lated to the actual medicine administered, can impact 
negatively on the credibility, adherence to and success of 
any health programme [13, 14], as well as adherence to 
any recommended treatments.
Over the years, spontaneous reporting of adverse 
events has been the easiest way of monitoring drug 
safety. However, spontaneous reporting is associated 
with serious under-reporting and more active method-
ologies, including cohort event monitoring (CEM) are 
currently recommended by the World Health Organi-
zation (WHO) to complement spontaneous reporting 
[15–17]. CEM is a prospective, observational cohort 
study of adverse events associated with one or more 
medicines [18]. It is an active form of safety surveil-
lance and records all clinical events and not just sus-
pected adverse reactions. In developing countries, 
CEM provides the possibility of obtaining more com-
plete safety data on medicines. Although more expen-
sive and intensive than spontaneous reporting, the 
CEM method offers numerous advantages, including 
the ability to obtain denominator values, calculate 
incidence rates, demonstrate the absence of harm, 
and provide indications of the risk factors for adverse 
reactions [19]. CEM studies in Africa usually involve 
follow-up of patients through home visits, a costly and 
time-consuming approach fraught with logistical chal-
lenges. Mobile phones, on the other hand could pro-
vide a convenient, safe and cost-effective alternative 
for collecting safety data in real-life settings [20].
Mobile phones in Africa are evolving from simple com-
munication tools into service delivery platforms, as seen 
with mobile money (M-Pesa) in Kenya. This has shifted 
the development paradigm surrounding mobile phones 
from one that simply reduces communication and coor-
dination costs to one that could transform lives through 
innovative applications and services. Over 60 % of Afri-
cans in cities and small villages own mobile phones [20, 
21]. Africans are buying mobile phones at a world record 
rate, with uptake soaring by 55 % in 5 years. Mobile sub-
scriptions in Africa rose from 54 million to almost 350 
million between 2003 and 2008, the fastest growth in the 
world. On average there are now 60 mobile subscriptions 
for every 100 people in the world. In developing coun-
tries overall, the figure stands at 48 for every 100 people. 
In Africa, penetration rates range from 16  % in Central 
African Republic, 43  % in Cameroon, to 84  % in South 
Africa [21]. A previous study showed that toll-free mobile 
phones offer a practical means of reporting adverse 
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reactions to anti-malarial drugs and may be a model of 
choice in Africa [21, 22], where mobile telephone pen-
etration and coverage is already driving innovation in 
agriculture and commerce. [22, 23] In a study by Fraser 
and Blaya, they concluded that the cost of mobile tech-
nology especially phones keep diminishing, making them 
the best alternatives for overcoming traditional obstacles 
to deliver health services to less resourced communities 
[24].
In Ghana, the mobile phone penetration rate at the end 
of August 2011 stood at 80.5 % [25]. The high penetration 
rates make the mobile phone a relevant and appropriate 
tool for improving health care delivery. According to the 
Dodowa Health and Demographic Surveillance System 
(HDSS) data, approximately 62  % of households in the 
surveillance area own mobile phones [26]. In recognition 
of the challenges of post-registration safety monitoring 
and limitations of spontaneous reporting, the INDEPTH 
Network Effectiveness and Safety Studies (INESS) on 
anti-malarial was initiated in Ghana, Tanzania, Mozam-
bique and Burkina Faso with funding from the Bill and 
Melinda Gates Foundation. In Ghana, these studies were 
conducted in three HDSS sites, including Dodowa. The 
platform has strengthened efforts to document and 
report adverse events (AEs) in resource-limited settings 
using CEM to follow-up patients treated with ACT for 
uncomplicated malaria. This study sought to examine the 
feasibility and cost of using mobile phones vis-à-vis the 
traditional home visits to monitor AEs associated with 




The Dangme West district, now Ningo-Prampram and 
Shai-Osudoku districts, is one of the peri-urban dis-
tricts in the Greater Accra Region of Ghana. It covers a 
land surface area of 1529 square kilometres with mainly 
coastal savannah vegetation. The district is divided into 
four sub-districts and seven area councils for administra-
tive purposes. There are 24 static health facilities and up 
to 20 outreach clinics delivering services in the district. 
Malaria is endemic in the district and is the leading cause 
of outpatient attendance. The Dodowa Health Research 
Centre (DHRC) maintains a HDSS, a longitudinal popu-
lation registration system that serves the district. Vital 
demographic events such as pregnancies, births, deaths, 
and migration are updated bi-annually. Verbal autopsies 
are conducted to elucidate the circumstances surround-
ing and possible causes of all recorded deaths. In order to 
enhance spatial analysis of the data being collected, geo-
graphic information system (GIS) has been incorporated 
into the HDSS activities.
Study design and sampling
This paper analysed CEM data gathered under real life 
conditions from February to December 2011. The CEM is 
the second aim of a multicentre phase IV INESS project 
that looked at a large cohort of about 10,000 participants 
from Ghana, Tanzania, Mozambique, and Burkina Faso. 
It was a prospective, cohort, non-interventional study 
intended to monitor the safety of the anti-malarial drugs 
using the spontaneous reporting system and cohort event 
monitoring under real life conditions. The data from the 
Dodowa HDSS, one of the research sites in Ghana that 
participated in the INESS project, were analysed. Patients 
prescribed anti-malarial were enrolled and followed up 
between day three (3) and day seven (7) of enrolment 
and all adverse events recorded. Patients were given the 
opportunity to report all adverse events of concern to 
the study team up to 28  days post drug administration. 
This process provides a real-life safety data in real time 
and complements the data obtained from spontaneous 
adverse event monitoring system.
Patients were recruited from both public and private 
health facilities in the district. All patients prescribed 
ACT for suspected or confirmed uncomplicated malaria 
were eligible for enrolment into the cohort. Patients were 
excluded if they had severe malaria, were in the first tri-
mester of pregnancy or declined to offer consent. Pre-
treatment questionnaires were administered to those 
who consented to participate at the time of recruitment 
at the health facility. Children 12–17 years assented and 
their parents/guardians gave consent. For those below 
12  years, the parents/guardians consented for them to 
be included and the parents/guardians were interviewed 
on follow-up. To prevent loss of any data relating to ACT 
and also to ascertain the treatment of malaria in the dis-
tricts, all patients presenting with uncomplicated malaria 
and prescribed an anti-malarial were recruited into the 
CEM study regardless of the actual anti-malarial pre-
scribed. However, only patients prescribed an ACT were 
included in the analyses. Data collected included basic 
demographic information (age and sex), symptoms expe-
rienced in the preceding 5 days, drugs (including herbal 
preparations) taken within the preceding 14 days, dosage 
of drugs taken, indications for use of the drugs, and the 
start and end dates for taking the drugs. The prescribed 
ACT and any other drugs dispensed on the day of enrol-
ment were recorded. The patient’s home address, con-
tact phone number(s) and/or phone number of a close 
contact were also recorded. The phone numbers were 
validated by test calls before the patients left the health 
facility to ensure correctness and availability of the num-
bers. Patients who provided phone numbers and agreed 
to be followed up on phone were shown the prescribed 
ACT and informed that questions asked during the 
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follow-up interview will be in relation to the prescribed 
ACT only. This was important and ensured that patients 
recognized that information to be collected during fol-
low-up interviews was based on the ACT they had been 
prescribed.
Follow‑up
The routine procedure of the health facilities for monitor-
ing adverse events is the use of the spontaneous adverse 
event monitoring system where patients are expected to 
come back to the facility to report any event experienced 
after drug intake. As part of the cohort event monitoring 
study protocol for monitoring and documenting these 
events, we use telephone calls and where this is not avail-
able, field officers went to the homes of the mothers or 
caretakers on motorbikes to conduct the interviews and 
document the events. Also, as part of the routine practice 
of the Research Centre, all field officers’ conduct moni-
toring using motorbikes for home visits and by phone 
calls.
Procedure for type of follow‑up
Two main types of follow-up procedures were used to 
document AEs experienced by patients prescribed ACT. 
Figure  1 shows the procedure by which patients were 
selected and followed-up using either telephone or home 
interview. Patients recruited for follow were asked to 
provide mobile phone numbers. Those without phone 
numbers were followed-up to their homes (as routinely 
done using motorbikes). Where the patients could not 
be reached on phone after three attempts on the inter-
view date, they were followed-up to the homes and inter-
viewed. Also those who had phone numbers but later 
disagreed to be interviewed on phone were also followed-
up to the home.
Follow-up was carried out by field officers assigned 
to each of the seven area councils in the district. Field 
officers followed up patients recruited from health facili-
ties located within their assigned area councils. Post-
treatment questionnaires included questions to find out 
if patients ingested the ACT completely as prescribed. 
If the response was ‘yes’, the start and end dates for 
taking the ACT were recorded; if ‘no’, reasons for non-
adherence were also recorded. For those who completed 
the treatment, new or worsening events and outcome 
for such events were recorded. A standard AE form 
was used to record the occurrence of all AEs regard-
less of severity and seriousness. The absence of any AE 
was also recorded to provide complete information on 
the safety of the medicines administered. All patients 
enrolled had only one active follow-up visit for safety 
assessment although patients had the team members’ 
phone details, permitting them to report AEs and obtain 
appropriate management for up to 28 days from the day 
of enrolment.
Data processing and analysis
Completed questionnaires were returned to the field 
office weekly. These were checked by a research assistant 
and any inconsistencies identified were checked and cor-
rected by contacting the field officer and/or patient. Data 
were double- entered using Epidata 3.1 and checked for 
inconsistency and coding errors. Data analysis was per-
formed using MS-Excel 2010 and STATA 11.3 (Stata 
Corp, College Station, TX, USA). Data were presented 
using simple frequencies and percentages in graphs 
and tables. Descriptive statistics were used to present 
the types of follow-up done and the AEs reported. To 
determine the cost of using the telephone, pre-paid call 
credit was supplied to all the supervisors conducting 
the follow-up. Each field officer had a logbook to record 
each patient’s study number, telephone number, date of 
interview and duration of each call made. The per-second 
billing rate of 0.70 Cedis (USD0.20) per minute of the 
mobile network Scancom Company Network (MTN) was 
used irrespective of the mobile phone network that each 
field supervisor used. Although the district had six active 
mobile phone service networks, the mobile telephone 
network (MTN) was used because its coverage extended 
to the entire district. For assessing the cost of home visit, 
each field officer rode a motorbike and was given fuel 
per week and by kilometres covered. They logged in the 
distance travelled per visit and the standard Dodowa 
Health Research Centre cost of 0.45 Cedis (USD0.30) per 
kilometre for motorbike usage was used. Microsoft Excel 
2010 was used to estimate the mean cost per interview 
conducted by phone and home visit.
Implication and limitations
The authors of this paper are of the view that, this is the 
first time a study like this has been conducted in a low 
resource setting like Ghana. The results from this study 
are consistent with existing evidence that the mobile 
phone can be used as a tool for improving health out-
comes in low resource settings. Notwithstanding this, the 
study presents some limitations. The authors did not use 
any rigorous systematic sampling procedure to select and 
assign patients to the type of follow-up. This may have 
introduced some discrepancies in the population selected 
and assignment of follow-up type. Also, we did not meas-
ure home distance variation among participants for home 
visit such as variations in the different routes leading to 
participants’ homes. For the phone calls, we did not use 
any standardized method of phone calling such as: call 
inquiry format, time of the day when calls were made and 
response of participants during busy periods.
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Results
Background of participants
A total of 4270 patients prescribed anti-malarials from 
21 health facilities in the Dangme West District (now 
Ningo-Prampram and Shai-Osudoku districts) were 
enrolled, 79/4270 (1.9  %) were lost to follow-up and 
67/4270 (1.6 %) patients withdrew their consent. Anal-
yses were performed on 4124 patients who were suc-
cessfully followed up. Sixty-three per cent (2599/4124) 
of the patients were females and 1126/4124 (27.3  %) 
were children under 5 years of age. The median age of 
patients was 15  years with an inter quartile range of 
29 years.
Means of follow‑up
Approximately 3586/4124 (86.9  %) of the patients pro-
vided mobile phone numbers at enrolment.
Of those successfully followed up, 2671/4124 (64.8 %) 
were interviewed by telephone and the remaining 
1453/4124 (35.2  %) were interviewed at home. On 
the whole, 3790/4124 (91.9  %) of the follow-up inter-
views were conducted within three to 7  days of ACT 
PATIENTS GIVEN ANTIMALARIAL AT RECRUITMENT
IS PHONE NUMBER 
AVAILABLE?
NO   YES




REACHED ON PHONE 
FOR INTERVIEW           
HOME VISIT INTERVIEW
NOYES
Fig. 1 A flow chart showing how the patients recruited were followed‑up via telephone or home visit
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intake, of which 2532/3790 (66.8  %) was by telephone 
and 1258/3790 (33.2  %) was by home visits (Table  1). 
On average 34 interviews were done at follow-up per 
day. Of these, an average of 37 and 28 interviews were 
conducted by telephone and home visits per day, 
respectively. Eighty-two per cent (2189/2671) of these 
interviews were conducted at the first attempt to contact 
the patient and only 1 % (26/2671) of the patients were 
interviewed after three or more attempts (Fig. 2).
Anti‑malarial prescribed
Three-thousand and sixty of the 4124 (74.2  %) patients 
were prescribed artesunate-amodiaquine (ASAQ), 
775/4124 (18.8  %) received artemether–lumefantrine 
(ALU) 208/4124 (5.1  %) received dihydroartemisinin–
piperaquine (DHA/PQP) and 81/4124 (2.0  %) received 
other anti-malarial drugs (artesunate monotherapy, 
amodiaquine monotherapy or sulfadoxine–pyrimeth-
amine). Of the 3060 patients who received ASAQ, 2098 
(68.6  %) received the co-blister tablet formulation and 
962 (31.4 %) received the fixed dose formulation.
Adverse events (AEs)
Of the 4124 patients who were successfully followed 
up, 1128/4124 (27.3  %) reported one or more AEs. 
Among the 1128 patients who reported AEs, a total 
of 1831 AEs were recorded with the reporting rates 
being higher among telephone contacts than by home 
visit. 1007/1831 (55  %) of AEs were reported through 
telephone call and 824/1831 (45 %) during home visits. 
Patients prescribed ASAQ reported 1589/1831 (86.8 %) 
of AEs and 242/1831 (13.2  %) from those on ALU. 
The overall average number of AEs reported was 1.46 
(SD = 0.77). Patients who received ASAQ reported an 
average of 1.49 (SD = 0.79) AEs and those who received 
ALU an average of 1.34 (SD = 0.68) was reported. The 
types and numbers of AEs reported for each of the 
ACT were comparable regardless of the type of follow-
up used to collect the safety information. Common 
events such as nausea, dizziness, diarrhoea, and vom-











0 10 20 30 40 50
Minutes used
Fig. 2 A graph showing the proportion of minutes used for follow‑
up by telephone call within 7 days of anti‑malaria intake
Table 1 Percentage of  attempts at  telephone call success 
within 7 days of anti-malaria intake
One attempt at telephone call—82 %, two attempts at telephone call—14 %, 
three attempts at telephone call—3 %, and more than three attempts at 
telephone call—1 %
Days of follow‑up Phone n (%) Home visit n (%) Total n (%)
3–7 2532 (94.8) 1258 (86.6) 3790 (91.9)
8–28 139 (5.2) 195 (13.4) 334 (8.1)
Total 2671 (100.0) 1453 (100.0) 4124 (100.0)
Table 2 Top 20 reported adverse events among  patients 
prescribed artesunate–amodiaquine during  follow-up 
contact by phone and home visit




n, % (95 % CI)
Home
n, % (95 % CI)
Total
n, % (95 % CI)
Drowsiness 225, 26.2 (23.3–29.3) 227, 31.1 (27.8–34.6) 452, 28.4 (26.2–30.7)
Dizziness 100, 11.6 (9.6–14.0) 80, 11.0 (8.8–13.5) 180, 11.3 (9.8–13.0)
General weak‑
ness
93, 10.8 (8.8–13.1) 57, 7.8 (6.0–10.0) 150, 9.4 (8.0–11.0)
Vomiting 67, 7.8 (6.1–9.8) 86, 11.8 (9.5–14.3) 153, 9.6 (8.2–11.2)
Loss of 
appetite
41, 4.8 (3.4–6.4) 14, 1.9 (1.1–3.2) 55, 3.5 (2.6–4.5)
Stomach ache 38, 4.4 (3.1–6.0) 30, 4.1 (2.8–5.8) 68, 4.3 (3.3–5.4)
Fever 38, 4.4 (3.1–6.0) 20, 2.7 (1.7–4.2) 58, 3.7 (2.8–4.7)
Headache 29, 3.4 (2.3–4.8) 20, 2.7 (1.7–4.2) 49, 3.1 (2.3–4.1)
Cough 29, 3.4 (2.3–4.8) 15, 2.1 (1.1–3.4) 44, 2.8 (2.0–3.7)
Diarrhoea 23, 2.7 (1.7–4.0) 20, 2.7 (1.7–4.2) 43, 2.7 (2.0–3.6)
Nausea 19, 2.2 (1.3–3.4) 33, 4.5 (3.1–6.3) 52, 3.3 (2.5–4.3)
Palpitation 17, 2.0 (1.1–3.1) 22, 3.0 (1.9–4.5) 39, 2.5 (1.8–3.3)
Chills 12, 1.4 (0.7–2.4) 6, 0.8 (0.3–1.8) 18, 1.1 (0.7–1.8)
Restlessness 10, 1.2 (0.6–2.1) 7, 1.0 (0.3–2.0) 17, 1.1 (0.6–1.7)
Body pain 9, 1.0 (0.5–2.0) 7, 1.0 (0.3–2.0) 16, 1.0 (0.5–1.6)
Sleeplessness 9, 1.0 (0.5–2.0) 6, 0.8 (0.3–1.8) 15, 0.9 (0.5–1.6)
Body itchiness 8, 0.9 (0.4–1.8) 10, 1.4 (0.7–2.5) 18, 1.1 (0.6–1.8)
Sore mouth 7, 0.8 (0.3–1.7) 4, 0.5 (0.1–1.4) 11, 0.7 (0.3–1.2)
Cold 7, 0.8 (0.3–1.7) 2, 0.3 (0.1–1.4) 9, 0.6 (0.2–1.1)
Skin rashes 7, 0.8 (0.3–1.7) 1, 0.1 (0.0–0.7) 8, 0.5 (0.2–1.0)
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Costing of type of follow‑up
For follow-up by telephone calls, the duration of calls 
ranged from 16  s to 53  min. These calls cost between 
0.26 Cedis (USD0.20) and 41.70 Cedis (USD27.0), respec-
tively. On average, the duration per call lasted 3 min 51 s 
(SD  =  3 min 21  s) estimated at 2.70 Cedis (USD0.77). 
Most of the telephone calls lasted for 5 min (Fig. 2) at an 
estimated cost of 13.50 Cedis (USD3.86). For follow-up 
by home visit, the distance per visit ranged from 0.65 to 
62  km. The distances travelled cost between 0.29 Cedis 
(USD0.20) to 279.00 Cedis (USD79.70). On average, the 
mean distance covered per visit was 10.7 (SD  =  8.61) 
costing 51.6 Cedis (USD14.74). Most of the distances 
covered were within 10  km (Fig.  3). Using the cost per 
type of follow-up for the 1128 individuals who reported 
AEs, the total cost of AEs reported by telephone inter-
views (1016 AEs) was 2743.20 Cedis (USD783.77) and 
home visit (815 AEs) was 3926.3 Cedis (USD1122.37). 
The cost of telephone call interviews was almost two 
times less than that of the cost of home visits.
Discussion
The objective of this paper was to examine the feasibility 
and cost of using mobile telephone vis-à-vis home visit to 
monitor adverse events (AEs) related to ACT for treat-
ment of uncomplicated malaria in peri-urban Ghana. 
Considering that 4124 out of 4270 patients were success-
fully followed upon telephone with majority responding 
on first attempt at call in the largely rural Dangme West 
District (now Ningo-Prampram and Shai-Osudoku), 
this was quite remarkable. Approximately 3586/4124 
(86.9  %) of the patients provided mobile phone num-
bers at enrolment This large number of patients in such a 
less endowed community like the Dangme West District 
confirms other studies that Africa has indeed witnessed 
a significant improvement in communication in many 
of its rural communities and Ghana is no exception [6]. 
Again, the provision of mobile phone numbers by such 
a large number on enrolment indicates that many of the 
patients had access and were connected to mobile net-
work; thus supporting the growing evidence that mobile 
communication has the potential of radically improving 
healthcare in the most remote and less endowed commu-
nities in the world [7].
Reporting rates of AEs proved slightly higher among 
telephone contacts than by home visit. This shows that 
mobile phones are a feasible option for collecting safety 
data, more especially as it was possible for majority of 
the patients to be interviewed within 7 days of medicine 
intake. This result confirms findings of previous studies 
where follow-up using mobile phones proved feasible for 
collecting data and monitoring desired health outcomes 
[27, 28].
Table 3 Top 20 reported adverse events among  patients 
prescribed arthemeter–lumefantrine during  follow-up 
contact by phone and home visit
a One patient could report more than one adverse event
Adverse eventsa Phone
N = 157
n, % (95 % CI)
Home
N = 85
n, % (95 % CI)
Total
N = 242
n, % (95 % CI)
Drowsiness 27, 17.2 (11.6–24.0)30, 35.3 (25.2–46.4) 57, 23.6 (18.4–29.4)
Dizziness 16, 10.2 (6.0–16.0) 8, 9.4 (4.2–17.7) 24, 9.9 (6.5–14.4)
General weakness 14, 8.9 (5.0–14.5) 3, 3.5 (1.01–0.10) 17, 7.0 (4.1–11.0)
Vomiting 12, 7.6 (4.0–13.0) 8, 9.4 (4.2–17.7) 20, 8.3 (5.1–12.5)
Headache 9, 5.7 (3.0–10.6) 3, 3.5 (0.7–10.0) 12, 5.0 (3.0–9.0)
Body pains 9, 5.7 (3.0–10.6) 0, 0.0 (0.0–4.2) 9, 3.7 (2.0–7.0)
Nausea 7, 4.5 (2.0–9.0) 2, 2.4 (0.3–8.2) 9, 3.7 (2.0–7.0)
Fever 7, 4.5 (2.0–9.0) 1, 1.2 (0.0–6.4) 8, 3.3 (1.4–6.4)
Stomach ache 6, 3.8 (1.4–8.1) 0, 0.0 (0.0–4.2) 6, 2.5 (1.0–5.3)
Chills 5, 3.2 (1.0–7.2) 0, 0.0 (0.0–4.2) 5, 2.1 (1.1–4.8)
Diarrhoea 4, 2.5 (1.0–6.3) 1, 1.2 (0.0–6.4) 5, 2.1 (1.1–4.8,)
Sleeplessness 4, 2.5 (1.0–6.3) 1, 1.2 (0.0–6.4) 5, 2.1 (1.1–4.8)
Cough 3, 1.9 (0.4–5.4) 5, 5.9 (2.0–13.2) 8, 3.3 (1.4–6.4)
Body itchiness 3, 1.9 (0.4–5.4) 3, 3.5 (1.0–1.1) 6, 2.5 (1.0–5.3)
Palpitation 3, 1.9 (0.4–5.4) 3, 3.5 (0.7–10.0) 6, 2.5 (1.0–5.3)
Loss of appetite 3, 1.9 (0.4–5.4) 1, 1.2 (0.0–6.4) 4, 1.7 (0.1–4.2)
Body itchiness 3, 1.9 (0.4–5.4) 3, 3.5 (07–10.0) 3, 1.2 (0.3–4.0)
Cold 3, 1.9 (0.4–5.4) 0, 0.0 (0.0–4.2) 3, 1.2 (0.3–4.0)
Chest pain 2, 1.3 (0.1–5.0) 0, 0.0 (0.0–4.2) 2, 0.8 (0.1–3.0)
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Fig. 3 A graph showing the distance covered for home visits within 
7 days of anti‑malaria intake
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On the basis of comparative cost analysis, the study 
revealed that for the follow up by telephone, the duration 
of calls ranged from 16 s to 53 min and cost between 0.26 
Cedis (USD0.20) and 41.70 Cedis (USD27.0) respectively 
while for the follow-up by home visit, the distance per 
visit ranged from 0.65 to 62 kilometres and cost between 
0.29 Cedis (USD0.20) to 279.00 Cedis (USD79.70). The 
cost per follow-up through home visit was much higher 
compared with that of the use of mobile phone. The 
average cost of obtaining AE feedback from patients 
who received anti-malarial through the mobile phone 
platform was far cheaper (USD2.00 per phone call) than 
through home visits (USD3.20 per visit). Telephone call 
cost was almost two times less than the cost of home 
visit. Aside the cost, time is also of essence; it took less 
time to get the needed feedback for prompt and other 
necessary action when using the mobile phone than 
the home visit This confirms a previous study that 
assessed the effectiveness, safety and cost of diabetes 
tele-management system, and found telephone call use 
to be safer and more cost-effective than the traditional 
health care of frequent physical visits for every drug [29]. 
The findings of this study is at variance with the study 
by Ryan et  al., who concluded that telephone moni-
toring expenses was an additional cost in the mobile 
group compared with paper-based monitoring [30, 31]. 
It is worth noting that the average cost for home visits 
estimated in this study covers only the direct cost of 
motorbike usage. Indirect costs such as travelling time, 
associated risk of riding the bike and the effects of the 
weather, were not included in the cost. While wear and 
tear on the phones may be apparent over time that of the 
motorbike cannot be overlooked. One advantage of this 
study confirms the findings of Asiimwe et al. that the use 
of mobile phone makes it easy for frontline health work-
ers to use mobile technology rather than the traditional 
home visit and paper-based reporting systems to gather 
and present health data with its inherent delays [7].
Other advantages related to the telephone inter-
views are that they are brief, specific and convenient for 
patients who may feel uncomfortable reporting in face-
to-face interviews. This confirms a previous study that 
examined whether an allied health professional tele-
phone visit could safely substitute for an in-person clinic 
visit and concluded that patients accepted telehealth as 
the exclusive means of follow-up and nearly all patients 
expressed great satisfaction with the telephone follow-up 
method [32, 33].
The types, frequencies, order and proportions of 
events reported by both methods of follow-up elic-
ited similar AEs reporting for each ACT dispensed. 
Important symptoms such as rashes, dizziness and sore 
mouth were picked by telephone call as well as for home 
visits for participants prescribed ASAQ. The top four AEs 
reported on telephone and at home visit for both ALU 
and ASAQ were similar. This corroborates the submis-
sion by Abedeji and colleagues that availability of a toll-
free telephone line may facilitate pharmacovigilance and 
follow-up of response to medicines in a poor resource 
setting [19]. This is the first report from Ghana that pro-
vides evidence of cost of safety monitoring of AEs using 
telephone and confirms a study by Dodoo et al. who rec-
ommended that future research around methods of col-
lection of AE data is transferable to rural settings [34].
Conclusion
Majority of patients were successfully followed up by 
telephone and most AEs were on phone. The cost of tel-
ephone interview was almost two times less than the cost 
of home visit. Mobile phones thus represent an efficient, 
less costly and effective means of monitoring drug safety 
in resource-limited settings as demonstrated by this 
study in Ghana. Typical setbacks of spontaneous report-
ing, mainly under-reporting of AEs, is worse in low-
resource settings such as Ghana and with the high mobile 
phone penetration, its use is the recommended method 
for collecting AEs as and when they occur, even in rural 
settings as propagated by Dodoo et al. [34].
Telephone calls and text messages may also reduce 
the problem of loss to follow-up which is unavoidable in 
the context of patients’ home visits [31]. Collecting AEs 
using the telephone can provide comprehensive real-life 
safety information on anti-malarials in resource-limited 
settings. The use of mobile phones to monitor health 
outcomes in Ghana and other developing countries in 
Africa will go a long way to reduce cost and maximize 
data collection within the health delivery systems of less 
resourced communities in the continent.
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